https://scholars.lib.ntu.edu.tw/handle/123456789/461876
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Ch'ang H.-J. | en_US |
dc.contributor.author | Huang C.-L. | en_US |
dc.contributor.author | HSIU-PO WANG | en_US |
dc.contributor.author | Shiah H.-S. | en_US |
dc.contributor.author | MING-CHU CHANG | en_US |
dc.contributor.author | Jan C.-M. | en_US |
dc.contributor.author | Chen J.-S. | en_US |
dc.contributor.author | YU-WEN TIEN | en_US |
dc.contributor.author | Hwang T.-L. | en_US |
dc.contributor.author | Lin J.-T. | en_US |
dc.contributor.author | ANN-LII CHENG | en_US |
dc.contributor.author | Whang-Peng J. | en_US |
dc.contributor.author | Chen L.-T. | en_US |
dc.creator | Chen L.-T.;Whang-Peng J.;Cheng A.-L.;Lin J.-T.;Hwang T.-L.;YU-WEN TIEN;Chen J.-S.;Jan C.-M.;Chang M.-C.;Shiah H.-S.;Wang H.-P.;Huang C.-L.;Ch'ang H.-J. | - |
dc.date.accessioned | 2020-02-20T06:53:15Z | - |
dc.date.available | 2020-02-20T06:53:15Z | - |
dc.date.issued | 2009 | - |
dc.identifier.issn | 0344-5704 | - |
dc.identifier.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-69049099928&doi=10.1007%2fs00280-009-0980-2&partnerID=40&md5=96013a846cf027043958a3b24ce9809d | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/461876 | - |
dc.description.abstract | Purpose: To evaluate the efficacy and safety profile of a triplet regimen consisting of gemcitabine, oxaliplatin, and infusional fluorouracil and leucovorin (LV) in advanced pancreatic carcinoma (APC). Patients and methods: Chemotherapy-na?ve patients with histo-/cytologically proven unresectable APC, and bi-dimensionally measurable diseases were eligible. Treatment consisted of fixed-dose rate (10 mg/m2/min) infusion of 800 mg/m2 gemcitabine followed by 2-h infusion of 85 mg/m2 oxaliplatin and then 48-h infusion of fluorouracil and LV (3,000 and 300 mg/m2, respectively) every 2 weeks (the GOFL regimen). The primary end-point was objective response rate. Results: Forty-five patients were enrolled and received a median of seven [95% confidence interval (CI) 6.4-8.8] cycles of treatment. On intent-to-treat analysis, the overall response and disease-control rates were 33.3% (95% CI 21.4-48.0%) and 68.9% (95% CI 54.8-83.0%), respectively. Clinical benefit response was observed in 46.2% of initially symptomatic patients. The median time-to-tumor progression and overall survival were 5.1 (95% CI 4.0-6.3) months and 8.7 (95% CI, 6.1-11.3) months, respectively. Major grade 3-4 toxicities were neutropenia (28.9%, with 4.4% complicated with fever), peripheral sensory neuropathy (15.6%), nausea/vomiting (13.3%), and diarrhea (6.7%). Conclusions: The triplet regimen is feasible and exhibits promising activity against APC, deserving further exploration. ? 2009 Springer-Verlag. | - |
dc.relation.ispartof | Cancer Chemotherapy and Pharmacology | - |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | alanine aminotransferase; fluorouracil; folinic acid; gemcitabine; oxalip; oxaliplatin; unclassified drug; adult; advanced cancer; aged; alanine aminotransferase blood level; anemia; article; asthenia; cancer combination chemotherapy; cancer patient; clinical article; clinical trial; diarrhea; drug efficacy; drug hypersensitivity; drug infusion; drug safety; drug withdrawal; feasibility study; febrile neutropenia; female; gastrointestinal hemorrhage; human; hyperammonemic encephalopathy; lung embolism; male; mucosa inflammation; multiple cycle treatment; nausea; neutropenia; overall survival; pancreas carcinoma; peripheral neuropathy; phase 2 clinical trial; priority journal; rash; sensory neuropathy; side effect; symptomatology; thrombocytopenia; treatment response; tumor growth; vomiting; Adult; Aged; Antineoplastic Agents; Deoxycytidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Fluorouracil; Humans; Kaplan-Meiers Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Organoplatinum Compounds; Pancreatic Neoplasms; Survival Rate; Treatment Outcome | - |
dc.title | Phase II study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of 5-fluorouracil/leucovorin (GOFL) in advanced pancreatic cancer | en_US |
dc.type | journal article | en |
dc.identifier.doi | 10.1007/s00280-009-0980-2 | - |
dc.identifier.pmid | 19319535 | - |
dc.identifier.scopus | 2-s2.0-69049099928 | - |
dc.relation.pages | 1173-1179 | - |
dc.relation.journalvolume | 64 | - |
dc.relation.journalissue | 6 | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.fulltext | no fulltext | - |
item.grantfulltext | none | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Integrated Diagnostics and Therapeutics-NTUH | - |
crisitem.author.dept | Surgery | - |
crisitem.author.dept | Surgery-NTUH | - |
crisitem.author.dept | Oncology | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0002-7741-9315 | - |
crisitem.author.orcid | 0000-0003-4896-7838 | - |
crisitem.author.orcid | 0000-0002-9126-2705 | - |
crisitem.author.orcid | 0000-0002-9152-6512 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。